| Autor: |
Moreno-Arquieta IA; Rheumatology Department, Universidad Autónoma de Nuevo León, Facultad de Medicina y Hospital Universitario 'Dr. José Eleuterio González', Monterrey, Mexico., Cardenas-de la Garza JA; Rheumatology Department, Universidad Autónoma de Nuevo León, Facultad de Medicina y Hospital Universitario 'Dr. José Eleuterio González', Monterrey, Mexico., Esquivel-Valerio JA; Rheumatology Department, Universidad Autónoma de Nuevo León, Facultad de Medicina y Hospital Universitario 'Dr. José Eleuterio González', Monterrey, Mexico., Riega-Torres J; Rheumatology Department, Universidad Autónoma de Nuevo León, Facultad de Medicina y Hospital Universitario 'Dr. José Eleuterio González', Monterrey, Mexico., Cuellar-Barboza A; Dermatology Department, Universidad Autónoma de Nuevo León, Facultad de Medicina y Hospital Universitario 'Dr. José Eleuterio González', Monterrey, Mexico., Herz-Ruelas ME; Dermatology Department, Universidad Autónoma de Nuevo León, Facultad de Medicina y Hospital Universitario 'Dr. José Eleuterio González', Monterrey, Mexico., Ocampo-Candiani J; Dermatology Department, Universidad Autónoma de Nuevo León, Facultad de Medicina y Hospital Universitario 'Dr. José Eleuterio González', Monterrey, Mexico., Galarza-Delgado DA; Rheumatology Department, Universidad Autónoma de Nuevo León, Facultad de Medicina y Hospital Universitario 'Dr. José Eleuterio González', Monterrey, Mexico. |
| Abstrakt: |
Eosinophilic fasciitis (EF) is an uncommon autoimmune connective tissue disorder characterized by edema, erythema, and subsequent induration of the extremities. It is commonly treated with corticosteroids but there is no treatment ladder for immunosuppressants or steroid-sparing agents. We report two EF cases treated effectively with mycophenolate mofetil (MMF) or mycophenolic acid (MPA) and present a literature review. We performed a MEDLINE search using the keywords 'eosinophilic fasciitis', 'Shulman syndrome', 'mycophenolic acid', or 'mofetil mycophenolate', and found 8 articles with 27 cases in which MMF or MPA was used. Twenty-nine cases were reviewed (2 reported herein and 27 from the literature search); all patients received a combination of systemic corticosteroids and MMF. MMF/MPA were given as a steroid-sparing agent in 27 (93.1%), in 1 (3.4%) as adjunctive therapy with other immunosuppressants, and in one, as monotherapy 1 (3.4%). Nineteen had a complete response, 6, a partial response, and 2 were unresponsive to diverse immunomodulators; in 2 cases, the outcome was not reported. MMF and MPA show promising therapeutic results and could be a treatment option to reduce corticosteroid related side effects. |
